Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426171 | 0.86 | — | — | |
| SCHEMBL78355 | 0.81 | KDM4E (0.59) | DNM1KDM4EPAOXHPGDPOLB | |
| SCHEMBL36169 | 0.81 | DNM1 (0.55) | DNM1KDM4EPAOXHPGDPOLB | |
| SCHEMBL427283 | 0.79 | KDM4E (0.61) | DNM1KDM4EPAOXHPGDPOLB | |
| SCHEMBL794226 | 0.79 | DNM1 (0.53) | DNM1KDM4EPAOXHPGDPOLB | |
| SCHEMBL24485546 | 0.79 | DNM1 (0.63) | DNM1KDM4EPAOXHPGDPOLB | |
| Hydrochloric Acid SCHEMBL10730965 | 0.79 | DNM1 (0.53) | DNM1KDM4EPAOXHPGDPOLB | |
| SCHEMBL10608974 | 0.79 | DNM1 (0.53) | DNM1KDM4EPAOXHPGDPOLB | |
| SCHEMBL4144564 | 0.78 | DNM1 (0.58) | DNM1KDM4EPAOXHPGDPOLB | |
| SCHEMBL11149127 | 0.77 | EPHX1 (0.58) | DNM1KDM4EPAOXHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011524411-A | — | — | 2011-09-01 | — | — | JP | claimed |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | claimed |
| US-7939548-B2 | Aminopyridines, e.g.,N-{[6-(aminomethyl)(2-pyridyl)]methyl}(2-{[2-(3-fluorophenyl)ethyl]amino}-5-(3-pyridyl)(3-pyridyl))carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-05-10 | — | — | US | claimed |
| US-7939534-B2 | e.g. (2-{[2-(3-fluorophenyl)ethyl]amino}-6-piperidyl(3-pyridyl))-N-(3-pyridylmethyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, chronic obstructive pulmonary disease, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-05-10 | — | — | US | claimed |
| US-7932270-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2011-04-26 | — | — | US | claimed |
| EP-2303861-A1 | PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | claimed |
| WO-2009153589-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | claimed |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | claimed |
| US-20080139575-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-06-12 | — | — | US | claimed |
| US-20080132545-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-06-05 | — | — | US | claimed |
| WO-2008016643-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | claimed |
| US-4057430-A | MEROCYANINE THIOHYDANTOIN SENSITIZERS | FUJI PHOTO FILM CO., LTD. (JA) | 1977-11-08 | — | — | US | claimed |
| EP-2303861-B1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2014-04-23 | — | — | EP | disclosed |
| US-8569298-B2 | Pyridine compounds | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-4040841-A | SENSITIZING DYE | FUJI PHOTO FILM CO., LTD. (JA) | 1977-08-09 | — | — | US | disclosed |
| US-4021251-A | Silver halide photographic emulsions | FUJI PHOTO FILM CO., LTD. (JA) | 1977-05-03 | — | — | US | disclosed |
| US-4014702-A | Silver halide photographic emulsion | FUJI PHOTO FILM CO., LTD. (JA) | 1977-03-29 | — | — | US | disclosed |
| US-3953216-A | BENZOXAZOLES, NAPHTHOXAZOLES | FUJI PHOTO FILM CO., LTD. (JA) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139575-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | DNM1 314/4885KDM4E 3309/4885PAOX 1058/4885 |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | GTF3C5, ZC3HAV1, POLI | DNM1 2083/4885KDM4E 1520/4885PAOX 1658/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | DNM1 1666/4885KDM4E 2725/4885PAOX 1003/4885 |
| US-20080132545-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | DNM1 314/4885KDM4E 3309/4885PAOX 1058/4885 |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | PTK2, PTK2B, PFKP | DNM1 1176/4885KDM4E 1747/4885PAOX 2640/4885 |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | DNM1 314/4885KDM4E 3309/4885PAOX 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.